Table 3 Ongoing phase 3 studies of newer radiosensitizers
From: Radiosensitizers in cervical cancer. Cisplatin and beyond
Arms | # Pat | Radiation |
|---|---|---|
CDDP 40 mg/m2 | 250 | EBRT 50.4 + brachyterapy |
Vs | Â | Â |
CDDP 40 mg/m2+ Gemcitabine 125 mg/m2 + Two post-brachy 21-day adjuvant courses CDDP 75 mg/m2/d1 plus Gemcitabine 1 gr/m2 d1&d8 | 250 | EBRT 50.4 + brachyterapy |
CDDP 40 mg/m2+ Gemcitabine 125 mg/m2 | 180 | EBRT 50 Gy in 2 Gy fractions+ Brachytherapy |
Vs | Â | Â |
CDDP 40 mg/m2+ Gemcitabine 125 mg/m2 | 180 | EBRT 50 Gy in 2 Gy fractions+ Radical hysterectomy |